Portfolio company
Beam Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops precision genetic medicines using base editing technology to treat patients with serious genetic diseases such as sickle cell disease.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Precision BioSciences
This company develops in vivo gene editing therapies for patients with genetic and infectious diseases using its proprietary ARCUS genome editing platform.
Bluebird Bio
This company develops and manufactures gene therapies for patients with severe genetic diseases, including sickle cell disease and beta-thalassaemia.
Be Biopharma
This company develops engineered B cell medicines to treat patients with hemophilia B, genetic diseases, and cancer.
Tessera
The company develops genome engineering platforms to write therapeutic DNA sequences into cells for clinicians and researchers treating genetic diseases.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Seamless Therapeutics
The company develops programmable recombinase-based gene editing therapies for patients with severe genetic diseases through its proprietary technology platform.
Ensoma
This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.